Endo International PLC(ENDP) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Current Price

$5.58

RSI

25.202

Beta:

1.556536

February 26, 2021
8.3B
-558.8M

-0.599 %
2.831 %
96.340 %
80.645 %

$2,903,074,000
$2,914,364,000
$2,947,078,000
$3,468,858,000
$4,010,274,000
$3,268,718,000
-0.389 %
-1.123 %
-17.705 %
-15.608 %
22.686 %

$-26,518,000
$-344,904,000
$-938,832,000
$-1,483,004,000
$-3,923,856,000
$-1,437,864,000
1200.641 %
172.201 %
57.963 %
164.588 %
-63.356 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.